Evidence map›Paper›PMID 41385766›Full record

ReviewMagyar onkologia2025

[Immunotherapy of cutaneous neoplasms].

Luca Ambrus, Tímea Balatoni

Abstract readReviewEnglish Abstract
In one paragraph

Review in Magyar onkologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Luca AmbrusOnkodermatológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary. ambrus.luca@oncol.hu.
Tímea BalatoniOnkodermatológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary. ambrus.luca@oncol.hu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Skin cancers are the most commonly diagnosed malignancies worldwide; however, effective treatment of advanced tumors was unavailable until recent years. In the past decade, the introduction of immune checkpoint inhibitors (ICIs), targeting CTLA-4, PD-1, PD-L1 and recently LAG-3, has revolutionized therapeutic strategies for advanced skin cancers and improved survival outcomes. In this review, we present the current therapeutic opportunities and future directions of immunotherapy in the management of malignant melanoma, cutaneous squamous cell carcinoma, basal cell carcinoma, and Merkel cell carcinoma, accompanied by a brief overview of their mechanisms of action. Ambrus L, Balatoni T. Immunotherapy of cutaneous neoplasms.

Indexed as

Immune Checkpoint InhibitorsImmunotherapyMelanomaSkin NeoplasmsB7-H1 AntigenBasal Cell CarcinomaCarcinoma, Merkel CellCarcinoma, Squamous CellCTLA-4 AntigenHumansProgrammed Cell Death 1 ReceptorB7-H1 AntigenCD274 protein, humanCTLA-4 AntigenCTLA4 protein, humanImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Identifiers

PMID41385766
PMCPMC12701786

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.